FDA Approves Lotemax 0.5% Gel Drop Formulation

Lotemax 0.5% (loteprednol etabonate ophthalmic gel; Bausch + Lomb), a corticosteroid indicated for the treatment of postoperative inflammation and pain following ocular surgery, has received FDA approval. Lotemax is a new topical corticosteroid formulation in Bausch + Lomb’s line of loteprednol ophthalmic products...

Full Story →